Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PARP inhibitor
Marketing
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
AZ and Merck were the first to grab an FDA approval for Lynparza, and, despite growing competition, the drug is set to remain top in the PARP space.
Ben Adams
Apr 24, 2024 8:23am
EU signs off on Merck and AZ's Lynparza after FDA delays ruling
Dec 21, 2022 9:43am
FDA delays review on AZ and Merck's Lynparza in prostate cancer
Dec 15, 2022 9:51am
AZ, MSD tap sports to spark prostate cancer conversations
Dec 14, 2022 7:45am
Loan default, Rubraca move inches Clovis closer to bankruptcy
Dec 5, 2022 10:25am
Lynparza phase 3 flops, leading Merck, AZ to end trial
Jul 19, 2022 12:17pm
